The Lancet Diabetes and Endocrinology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Muscle matters: the effects of medically induced weight loss on skeletal muscle..
12:785-787.
2024
-
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply.
12:519-519.
2024
-
Call for effective therapies for preventing dementia in people with type 2 diabetes.
12:510-513.
2024
-
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study.
12:330-338.
2024
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
12:306-319.
2024
-
How clinically relevant is statin-induced diabetes?.
12:286-287.
2024
-
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants.
12:107-118.
2024
-
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study.
11:333-344.
2023
-
Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status.
10:831-832.
2022
-
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
10:645-654.
2022
-
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
10:655-667.
2022
-
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019.
10:177-192.
2022
-
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
10:35-45.
2022
-
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
9:653-662.
2021
-
Erectile dysfunction in men with type 2 diabetes treated with dulaglutide: an explanatory analysis of the REWIND placebo-controlled randomised controlled trial (vol 9, pg 484, 2021).
9:E3-E3.
2021
-
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
9:484-490.
2021
-
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.
9:276-292.
2021
-
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
8:834-844.
2020
-
Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study.
8:572-581.
2020
-
Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials.
8:557-558.
2020
-
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
8:106-114.
2020
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
7:618-628.
2019
-
Change in albuminuria as a surrogate endpoint in chronic kidney disease.
7:335-335.
2019
-
Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study.
7:34-43.
2019
-
Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care.
7:4-5.
2019
-
Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study.
6:790-797.
2018
-
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.
6:798-808.
2018
-
Do sulphonylureas still have a place in clinical practice?.
6:821-832.
2018
-
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
6:445-454.
2018
-
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
5:877-886.
2017
-
Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study.
5:774-787.
2017
-
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
5:597-609.
2017
-
Microvascular outcomes in type 2 diabetes – Authors' reply.
5:580-580.
2017
-
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
5:534-543.
2017
-
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
5:431-437.
2017
-
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
5:97-105.
2017
-
Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.
4:S18-S18.
2016
-
Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.
4:244-253.
2016
-
Myostatin inhibition for treatment of sarcopenia.
3:917-918.
2015
-
Diagnostic criteria for osteoporosis should be expanded.
3:234-236.
2015
-
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
2:843-851.
2014
-
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial.
2:562-572.
2014
-
Dysglycaemia, vasculopenia, and the chronic consequences of diabetes.
1:71-78.
2013
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)